Ua hoʻolaha ʻo Moleac i ka hoʻokuʻu ʻana i nā hopena noiʻi ATHENE, i paʻi ʻia ma ka Journal of the American Medical Director Association (JAMDA).
ʻO nā lāʻau lapaʻau i hiki ke hoʻolōʻihi i ke kaʻina o AD i kona hiki ʻana i ke kahua lapaʻau, e noho mau i kahi pono olakino koʻikoʻi. Ua hōʻike ʻo NeuroAiD™II i nā hopena modulatory i ka amyloid precursor protein (APP) processing2 a me ka hoʻololi ʻana o ka protein tau i nā ʻano phosphorylated a aggregated abnormally3, a me nā waiwai neuro-regenerative a me neuro-restorative4. Ua hōʻike mua ʻia nā hopena maikaʻi o NeuroAiD™II ma nā hana cognitive impaired i ka ʻeha lolo traumatic5.
ʻO ka Alzheimer's Disease Therapy me NEuroaid (ATHENE) Study ka haʻawina mua e loiloi i ka palekana a me ka pono o NeuroAiD™II i nā maʻi AD haʻahaʻa a paʻa i nā maʻi maʻamau maʻamau.
ʻO ATHENE kahi hoʻāʻo ʻelua-makapō i hoʻopaʻa ʻia ma kahi o 6 mau mahina a ukali ʻia e ka hoʻonui ʻia ʻana o ka lepili o ka lāʻau NeuroAiD™II no 6 mau mahina. Ua hoʻokomo ʻia nā kumuhana 125 mai Singapore i ka hoʻokolokolo, i hoʻonohonoho ʻia e ka Memory Aging and Cognition Center, National University Health System, National Neuroscience Institute, a me St. Luke's Hospital, Singapore.
• Ua hōʻike ʻo NeuroAiD™II i ka palekana no ka wā lōʻihi ma ke ʻano he lāʻau hoʻohui i AD me ka piʻi ʻole o ka poʻe maʻi e loaʻa ana i nā hopena koʻikoʻi a i ʻole nā hopena ʻino.
• ʻO ka hoʻomaka mua ʻana o NeuroAiD™II ua hāʻawi i ka hoʻomaikaʻi lōʻihi o ka cognition i hoʻohālikelike ʻia me kahi placebo (hui hoʻomaka hope) i ana ʻia e ka ADAS-cog, koʻikoʻi i ka helu ma 9 mau mahina, a me ka lohi i ka emi ʻana o ka manawa.
Kākoʻo nā hopena haʻawina ʻo ATHENE i ka pōmaikaʻi o NeuroAiD™II ma ke ʻano he lāʻau hoʻohui palekana i ka mālama maʻamau AD ma muli o ka loaʻa ʻole o ka hōʻike hōʻike o ka piʻi nui ʻana o nā hanana ʻino ma waena o MLC901 a me kahi placebo. Hōʻike nā loiloi i ka hiki o MLC901 i ka hoʻolōʻihi ʻana i ka piʻi ʻana o AD e kūlike me nā haʻawina preclinical a me nā noiʻi lapaʻau i paʻi mua ʻia, e lilo ia i mea lapaʻau hoʻohiki no nā maʻi maʻi AD. Pono kēia mau hopena i ka hōʻoia hou ʻana i nā haʻawina nui a lōʻihi.
He olelo na ka Luna Imi Nui
"ʻO ka maʻi Alzheimer ke kumu maʻamau o ka dementia, helu ʻia no 60-80% o nā hihia. Ma mua o ka ʻae ʻia ʻana o ka aducanumab e ka FDA, ʻaʻohe maʻi hoʻololi i ka mālama ʻana no ka maʻi Alzheimer, a ʻo nā lāʻau hōʻailona e loaʻa nei i kēia manawa ke ʻimi nei e hoʻopaneʻe iki i ka piʻi ʻana o nā hōʻailona dementia a hoʻomaikaʻi i ka maikaʻi o ke ola no ka poʻe me Alzheimer a me kā lākou mea mālama. No laila, pono e hāʻawi i nā mea maʻi a me kā lākou mea mālama i ke komo mua i ka maʻi maʻi a me nā lāʻau lapaʻau hou.
Pono e hoʻomaopopo ʻia nā hopena i hoʻohiki ʻia o ke aʻo ʻana ʻo ATHENE ma ke ʻano he ʻāpana o ka hoʻololi ʻana o ka pipeline hoʻomohala lāʻau maʻi Alzheimer mai ka hōʻailona i nā maʻi hoʻololi i nā maʻi. Pono e loiloi ʻia kēia noiʻi a me nā lāʻau lapaʻau ʻē aʻe e nā hoʻokolohua lapaʻau i hoʻolālā maikaʻi ʻia.
Kumu Christopher Chen
Luna Hoʻokele, Memory Aging and Cognition Center, National University Health System and Associate Professor, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore.
He aha e lawe ʻia mai kēia ʻatikala:
- Until the recent approval of aducanumab by the FDA, there was no disease modifying treatment for Alzheimer’s Disease, and the currently available symptomatic treatments seek to temporarily delay the worsening of dementia symptoms and improve the quality of life for those with Alzheimer’s and their caregivers.
- ATHENE study results support the benefit of NeuroAiD™II as a safe add-on therapy to standard AD treatment as the study found no evidence of a significant increase in adverse events between MLC901 and placebo.
- ʻO ka Alzheimer's Disease Therapy me NEuroaid (ATHENE) Study ka haʻawina mua e loiloi i ka palekana a me ka pono o NeuroAiD™II i nā maʻi AD haʻahaʻa a paʻa i nā maʻi maʻamau maʻamau.
